<!-- mobian-agent-page publisher="dailydev" canonical="https://daily.dev/posts/bytedance-s-ai-drug-unit-anew-labs-raises-290m-at-1-5b-valuation-reuters-reports-igbtigrgt" -->

---
title: ByteDance’s AI drug unit Anew Labs raises $290M at $1.5B...
description: ByteDance's AI drug discovery spin-off, Anew Labs, closed a $290M funding round at a $1.5B valuation, with ByteDance retaining 56% ownership, according to...
canonical: https://daily.dev/posts/bytedance-s-ai-drug-unit-anew-labs-raises-290m-at-1-5b-valuation-reuters-reports-igbtigrgt
twitter:card: summary_large_image
twitter:site: @dailydotdev
og:type: website
og:site_name: daily.dev
og:title: ByteDance’s AI drug unit Anew Labs raises $290M at $1.5B valuation, Reuters reports | daily.dev
og:description: ByteDance's AI drug discovery spin-off, Anew Labs, closed a $290M funding round at a $1.5B valuation, with ByteDance retaining 56% ownership, according to...
og:url: https://daily.dev/posts/bytedance-s-ai-drug-unit-anew-labs-raises-290m-at-1-5b-valuation-reuters-reports-igbtigrgt
og:image: https://api.daily.dev/og/posts/IgbtiGRGT.png
og:image:alt: ByteDance’s AI drug unit Anew Labs raises $290M at $1.5B valuation, Reuters reports
og:image:width: 1200
og:image:height: 630
og:locale: en
---

> ## Documentation Index
> Fetch the complete documentation index at: https://daily.dev/llms.txt
> Use this file to discover all available pages before exploring further.

# ByteDance’s AI drug unit Anew Labs raises $290M at $1.5B valuation, Reuters reports

**[The Next Web](https://daily.dev/sources/tnw)** · 2 min read · 0 upvotes · 0 comments

## Summary

ByteDance's AI drug discovery spin-off, Anew Labs, closed a $290M funding round at a $1.5B valuation, with ByteDance retaining 56% ownership, according to Reuters citing two sources. HSG (formerly Sequoia China), IDG Capital, and Hillhouse Investment led the round, joined by 5Y Capital, Gaorong Ventures, Primavera, Boyu Capital, the state-backed Shanghai Future Industries Fund, and SBP Group as a strategic investor. The unit, led by former IDG Capital VC Liu Kai, develops structure-prediction and protein-design models like Protenix and PXDesign and has produced drug candidates including an AI-designed IL-17 inhibitor. Anew Labs operates out of Shanghai, Singapore, and San Jose, with Volcano Engine continuing to supply its computing infrastructure.

## Full article

daily.dev links to this article rather than hosting it. Read it at the original source: <https://thenextweb.com/news/bytedance-anew-labs-290m-ai-drug-discovery>

## Questions this post answers

### How much funding did ByteDance's AI drug discovery unit Anew Labs raise and at what valuation?

Anew Labs raised $290 million at a $1.5 billion valuation. ByteDance retains 56% of the business after the round, which was led by HSG (formerly Sequoia China), IDG Capital, and Hillhouse Investment, with 5Y Capital as co-lead and participation from Gaorong Ventures, Primavera Venture Partners, Boyu Capital, the Shanghai Future Industries Fund, and SBP Group.

_Investors tracking AI-in-science funding rounds follow deals like this one on daily.dev._

### What drug candidates or models has ByteDance's Anew Labs developed?

Anew Labs has developed structure-prediction and protein-design models called Protenix and PXDesign, plus a small number of drug candidates. One notable example is an AI-designed IL-17 inhibitor, shown by biology department head Chris Li at the American Association of Immunologists' meeting in Boston, one of four candidates the unit has produced so far.

_Developers curious about AI-for-science applications keep up with efforts like Anew Labs's on daily.dev._

## Similar posts on daily.dev

- [ByteDance's Anew Labs presents first AI-designed therapy as TikTok parent enters drug discovery race](https://daily.dev/posts/bytedance-s-anew-labs-presents-first-ai-designed-therapy-as-tiktok-parent-enters-drug-discovery-race-hceepfm3z) · The Next Web · 0 upvotes · 0 comments
- [AI is spitting out more potential drugs than ever. This start-up wants to figure out which ones matter.](https://daily.dev/posts/ai-is-spitting-out-more-potential-drugs-than-ever-this-start-up-wants-to-figure-out-which-ones-matt-usqozoajm) · TechCrunch · 0 upvotes · 0 comments
- [MindRank’s oral GLP-1 is the furthest along any AI-native drug programme](https://daily.dev/posts/mindrank-s-oral-glp-1-is-the-furthest-along-any-ai-native-drug-programme-xo5boxlke) · The Next Web · 0 upvotes · 0 comments

---

Tags: [#health-tech](https://daily.dev/tags/health-tech)

[View this post on daily.dev](https://daily.dev/posts/bytedance-s-ai-drug-unit-anew-labs-raises-290m-at-1-5b-valuation-reuters-reports-igbtigrgt)

```json
{"@context":"https://schema.org","@graph":[{"@type":"Organization","@id":"https://daily.dev/#organization","name":"daily.dev","url":"https://daily.dev","logo":{"@type":"ImageObject","url":"https://daily.dev/apple-touch-icon.png","width":180,"height":180},"sameAs":["https://twitter.com/dailydotdev","https://github.com/dailydotdev","https://www.linkedin.com/company/daily-dev-ltd"]},{"@type":"WebSite","@id":"https://daily.dev/#website","url":"https://daily.dev","name":"daily.dev","publisher":{"@id":"https://daily.dev/#organization"},"potentialAction":{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https://daily.dev/search?q={search_term_string}"},"query-input":"required name=search_term_string"}}]}
{"@context":"https://schema.org","@type":"TechArticle","headline":"ByteDance’s AI drug unit Anew Labs raises $290M at $1.5B valuation, Reuters reports","url":"https://daily.dev/posts/bytedance-s-ai-drug-unit-anew-labs-raises-290m-at-1-5b-valuation-reuters-reports-igbtigrgt","mainEntityOfPage":{"@type":"WebPage","@id":"https://daily.dev/posts/bytedance-s-ai-drug-unit-anew-labs-raises-290m-at-1-5b-valuation-reuters-reports-igbtigrgt"},"datePublished":"2026-09-16T08:18:27.156Z","dateModified":"2026-09-16T08:18:48.868Z","description":"ByteDance's AI drug discovery spin-off, Anew Labs, closed a $290M funding round at a $1.5B valuation, with ByteDance retaining 56% ownership, according to...","image":"https://media.daily.dev/image/upload/f_auto,q_auto/v1/posts/7400e6a86938588a051d0dd5582b006a?_a=AQAEuop","thumbnailUrl":"https://media.daily.dev/image/upload/f_auto,q_auto/v1/posts/7400e6a86938588a051d0dd5582b006a?_a=AQAEuop","isAccessibleForFree":true,"articleSection":"The Next Web","inLanguage":"en","publisher":{"@type":"Organization","name":"daily.dev","url":"https://daily.dev","logo":{"@type":"ImageObject","url":"https://daily.dev/apple-touch-icon.png","width":180,"height":180}},"author":{"@type":"Organization","name":"The Next Web","logo":"https://media.daily.dev/image/upload/t_logo,f_auto/v1/logos/tnw","url":"https://daily.dev/sources/tnw"},"commentCount":0,"discussionUrl":"https://daily.dev/posts/bytedance-s-ai-drug-unit-anew-labs-raises-290m-at-1-5b-valuation-reuters-reports-igbtigrgt","interactionStatistic":[{"@type":"InteractionCounter","interactionType":{"@type":"LikeAction"},"userInteractionCount":0},{"@type":"InteractionCounter","interactionType":{"@type":"CommentAction"},"userInteractionCount":0}],"keywords":"health-tech","timeRequired":"PT2M"}
{"@context":"https://schema.org","@type":"BreadcrumbList","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https://daily.dev"},{"@type":"ListItem","position":2,"name":"The Next Web","item":"https://daily.dev/sources/tnw"},{"@type":"ListItem","position":3,"name":"ByteDance’s AI drug unit Anew Labs raises $290M at $1.5B valuation, Reuters reports"}]}
{"@context":"https://schema.org","@type":"FAQPage","@id":"https://daily.dev/posts/bytedance-s-ai-drug-unit-anew-labs-raises-290m-at-1-5b-valuation-reuters-reports-igbtigrgt#faq","mainEntity":[{"@type":"Question","name":"How much funding did ByteDance's AI drug discovery unit Anew Labs raise and at what valuation?","acceptedAnswer":{"@type":"Answer","text":"Anew Labs raised $290 million at a $1.5 billion valuation. ByteDance retains 56% of the business after the round, which was led by HSG (formerly Sequoia China), IDG Capital, and Hillhouse Investment, with 5Y Capital as co-lead and participation from Gaorong Ventures, Primavera Venture Partners, Boyu Capital, the Shanghai Future Industries Fund, and SBP Group. Investors tracking AI-in-science funding rounds follow deals like this one on daily.dev."}},{"@type":"Question","name":"What drug candidates or models has ByteDance's Anew Labs developed?","acceptedAnswer":{"@type":"Answer","text":"Anew Labs has developed structure-prediction and protein-design models called Protenix and PXDesign, plus a small number of drug candidates. One notable example is an AI-designed IL-17 inhibitor, shown by biology department head Chris Li at the American Association of Immunologists' meeting in Boston, one of four candidates the unit has produced so far. Developers curious about AI-for-science applications keep up with efforts like Anew Labs's on daily.dev."}}]}
```

